Physician profile
John L Brazill
NPI 1144238429
$9,572.19
in general payments reported to CMS, 2019-2025
14 companies · $78.62 in 2025
The $78.62 reported for 2025 was more than what a typical Anesthesiology provider received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,737 · 2020: $2,009 · 2021: $1,496 · 2022: $1,139 · 2023: $692 · 2024: $421 · 2025: $78.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,570.58 | 2019-2025 | General - Pain Management, Na, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $1,933.56 | 2019-2024 | Eterna, Proclaim |
| Vertiflex, INC. | $1,605.83 | 2019 | |
| Nevro Corp. | $457.52 | 2019-2022 | |
| Stimwave Technologies Incorporated | $424.86 | 2019 | |
| Medtronic USA, INC. | $185.95 | 2019-2020 | |
| Medtronic, INC. | $184.26 | 2021-2023 | Kyphon Express II Kyphopak Tray |
| Abbvie INC. | $89.02 | 2021 | |
| Scilex Pharmaceuticals INC. | $30.62 | 2019-2020 | |
| Forte Bio-Pharma LLC | $23.59 | 2024 | Prolate, Nalocet |
| Teva Pharmaceuticals USA, INC. | $20.67 | 2019 | |
| Collegium Pharmaceutical, INC. | $20.18 | 2024 | Xtampza |
| Foundation Fusion Solutions, LLC | $12.92 | 2024 | |
| Mdd US Operations, LLC | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brazill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.